Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in
severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with
elevated eosinophil levels.